The burgeoning popularity of semaglutide , initially for blood sugar control , is creating significant interest within the UK , prompting a notable shift in hormone trends. Access these compounds remains a complex landscape, with NHS provision currently limited and independent providers offering therapy at a substantial price. Concerns are being ra